CRSP News and Press, CRISPR Therapeutics AG From 12/17/23

2023-12-17 08:45:00 ET Building a better proverbial mousetrap isn't always a necessary condition for the success of a business, but doing so can help. Those corporations that break new ground often end up being handsomely rewarded, as are those investors bold enough to hold shares of these ...

2023-12-16 09:45:00 ET On Dec. 8, CRISPR Therapeutics (NASDAQ: CRSP) and its collaboration partner Vertex Pharmaceuticals (NASDAQ: VRTX) made history when the Food and Drug Administration (FDA) gave them the green light to commercialize their gene therapy for sickle cell dis...

2023-12-16 06:55:00 ET You might think that the stock market would be really quiet during the holidays. After all, many investors are on vacation and take a break from buying and selling stocks. Interestingly, though, the S&P 500 often rises noticeably in the final five trading days...

2023-12-16 05:53:00 ET It's now a new ballgame for CRISPR Therapeutics (NASDAQ: CRSP) . The company, along with its big partner, Vertex Pharmaceuticals (NASDAQ: VRTX) , won U.S. regulatory approval for Casgevy (exa-cel) in treating sickle cell disease (SCD) on Dec. 8, 2023. ...

2023-12-15 11:56:19 ET More on CRISPR Therapeutics, Vertex Pharmaceuticals, etc. Vertex's Pain Game: VX-548 Takes Aim At Neuropathic Battles Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed CRISPR Gene Editing: Intellia Vs. Crispr T...

2023-12-15 05:30:00 ET CRISPR Therapeutics (NASDAQ: CRSP) scored a major win in recent days, earning the world's first regulatory nod for a CRISPR-based gene-editing treatment. The U.S. Food and Drug Administration (FDA) approved Casgevy (developed as exa-cel) for sickle cell diseas...

2023-12-13 09:47:07 ET Verizon Communications Inc (VZ) VZ is trading DOWN for the last 4 days, and it at trading at $36.83 with volume of 4,933,910 and a one day change of $-0.47 (-1.26%). Verizon Communications Inc has a 52-week low of 30.74 and a 52-week high of $42.58. The busine...

2023-12-13 09:33:01 ET More on Editas, Vertex, etc. Editas Medicine, Inc. (EDIT) EDIT-301 Program Update: RUBY and EdiTHAL Trials Data Update (Transcript) Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed Editas Medicine, Inc. (EDIT)...

2023-12-12 06:00:00 ET Intellia Therapeutics (NASDAQ: NTLA) and CRISPR Therapeutics (NASDAQ: CRSP) have one big thing in common: They both specialize in the hot area of gene editing, or the repairing of faulty genes responsible for disease. But CRISPR Therapeutics is farther...

2023-12-11 12:41:31 ET On Monday, for the third straight day, shares of CRISPR Therapeutics (NASDAQ: CRSP) stock declined, falling 11.2% through 11:30 a.m. ET -- which is kind of crazy when you think about it. Just three days ago, CRISPR announced that the U.S. Food and Drug...